Induced pluripotent stem cells (iPSCs) are derived from terminally differentiated somatic cells, which have been genetically reprogrammed to become pluripotent. They do not require fertilized eggs as their source, thus overcoming many of the practical and ethical limitations of using embryonic stem (ES) cells. iPSCs can be generated from any type of adult tissue cell, such as adipose stem cells, amniotic cells, dental pulp cells, and skin fibroblasts. iPSCs are capable of large-scale production of various cell types. iPSCs and their derivatives offer an invaluable tool for in vitro disease modeling, the discovery and development of novel therapeutics, toxicity studies, and other scientific fields.
Various cell models constructed with iPSC derivatives are similar to in vivo or primary cell counterparts at the transcriptional, cellular, and functional levels, while having little interference with genetic content. Using iPSCs derived cells is easier than obtaining and maintaining their primary tissue-derived counterparts. Moreover, iPSCs have the added benefit of being easily manipulated by genome editing technologies such as CRISPR-Cas9 and transcription activator-like effector nucleases (TALENs). Human iPSCs containing the genotypes responsible for human disease hold promise for the development of novel cell therapies, as well as research models for inherited and acquired diseases. The differentiated cells from reprogrammed patient-specific human iPSCs retain disease-associated phenotypes.
Amerigo Scientific provides a range of high-purity, high-quality iPSC-derived cells and engineered reporter iPSC-derived cells for studying the molecular mechanisms of diseases, performing high-throughput drug screening, and developing cell therapies, among other applications.
.
